Ipsen and Sutro Biopharma entered a global licensing deal for STRO-003, an ADC targeting ROR1, overexpressed in cancers, marking Ipsen's first ADC portfolio addition.United States, New York, Jan. 31, ...

A breakthrough discovery in enzyme science could revolutionize the treatment of autoimmune disorders and other diseases tied ...

Saliva-based diagnostics have emerged as a transformative approach in medical testing, offering a non-invasive and efficient ...

Antibodies are immune proteins produced by B-white blood cells (a type of immune cell) to help the body fight against infections. There are several types of antibodies, and IgG antibodies are ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NEW YORK — Werfen said Monday that it has received US Food and Drug Administration 510(k) clearance for its Aptiva Antiphospholipid Syndrome (APS) Immunoglobulin G (IgG) and Immunoglobulin M (IgM) ...

IGM Biosciences announced a strategic update to halt the development of two antibody therapies, imvotamab and IGM-2644, for autoimmune diseases due to insufficient results and strategic ...

Small molecules like fentanyl do not bind major histocompatibility complex (MHC) molecules and so are not presented to T cells by MHC-bearing antigen presenting cells, an essential step in the ...

On Friday, BMO Capital Markets adjusted its stance on IGM Biosciences (NASDAQ:IGMS) stock, downgrading the company from Outperform to Market Perform. The firm also significantly reduced the price ...

The company now lists a lone, Sanofi-partnered IgM antibody asset on its pipeline. The treatment, which the partners hope to pit against immunology and inflammation targets, is still in the ...